A new model for limbal transplantation using E-GFP for follow-up of transplant survival.
Limbal transplants in humans show a high rate of rejection even under local and systemic immunotherapy. In order to test immunomodulatory treatments a new limbal transplant model in the rat was developed using enhanced green fluorescent protein (E-GFP) as marker for follow-up. Sixty E-GFP-positive limbal transplants from Sprague-Dawley TgN(act-EGFP)Osb4 rats were transplanted onto 18 wild-type inbred Sprague-Dawley (isografts) rats, six wild-type litter mate Sprague-Dawley (sibling) rats, 18 Fischer 344 (allografts) rats, and 18 Fischer 344 rats depleted from monocytes and macrophages by subconjunctival treatment with clodronate liposomes. All rats were monitored three times a week with fluorescence microscopy, until fluorescence had disappeared. At postoperative days 6, 9, 12, and 15, three rats of all groups were killed for immunohistochemical analysis of infiltrating cells. Using a modified digital fluorescence microscope, we were able to monitor transplant behavior over time without disturbance of the ocular surface. The average days of rejection were 14 days in the isograft group, the sibling group, and the untreated allograft group. However, the average day of rejection in the allogeneic macrophage-depleted group was 27 days. Marked infiltration of macrophages and lymphocytes was seen in the untreated isografts and allografts. In the clodronate liposome-treated allografts infiltration was minor. A successful new limbal transplant model is described. The transplant can be accurately followed up in vivo by E-GFP labeling of the donor tissue without disturbing the corneal surface. Although E-GFP itself proved to be immunogenic, local clodronate liposome injections significantly increased graft survival. So the model seems to be useful for testing immunosuppressive or modulatory agents in limbal transplantation studies.
Keijser
S
S
Department of Ophthalmology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
de Keizer
R J W
RJ
Prins
F A
FA
Tanke
H J
HJ
van Rooijen
N
N
Vrensen
G F J M
GF
Jager
M J
MJ
D000818:Animals; D000941:Antigens / Q000276:immunology; D015415:Biomarkers / Q000032:analysis; D004002:Clodronic Acid / Q000008:administration & dosage; D016039:Corneal Transplantation / Q000276:immunology / Q000379:methods*; D005260:Female; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000276:immunology*; D049452:Green Fluorescent Proteins / Q000032:analysis*; D007150:Immunohistochemistry / Q000379:methods; D016850:Limbus Corneae / Q000276:immunology / Q000601:surgery*; D008081:Liposomes; D049408:Luminescent Agents / Q000032:analysis*; D008214:Lymphocytes / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D008856:Microscopy, Fluorescence / Q000379:methods; D023421:Models, Animal; D051381:Rats; D011916:Rats, Inbred F344; D017207:Rats, Sprague-Dawley
D000941:Antigens; D015415:Biomarkers; D008081:Liposomes; D049408:Luminescent Agents; D004002:Clodronic Acid; D049452:Green Fluorescent Proteins